1.
Cosimi AB, Urton B, Colvin RB, Goldstein G, Laquaglia MP, N NT, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation.
1981;32(6):535–9.
2.
Reichert JM. Marketed therapeutic antibodies compendium. MAbs. 2012;4(3):413–5.
3.
Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly
diabetic NOD mice. J Immunol. 1997;158(6):2947–54.
4.
Chatenoud L, Bluestone JA. CD3-specific antibodies: A portal to the treatment of autoimmunity.
Nat Rev Immunol. 2007;7(8):622–32.
5.
Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, et al. Modified anti-CD3
therapy in psoriatic arthritis: A Phase I/II clinical trial. J Rheumatol. 2002;29(9):1907–13.
6.
Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1
diabetes mellitus. Clin Immunol. 2013;149(3):268–78.
7.
You S, Zuber J, Kuhn C, Baas M, Valette F, Sauvaget V, et al. Induction of Allograft
Tolerance by Monoclonal CD3 Antibodies : A Matter of Timing. Am J Transl Res. 2012;12(11):2909–19.
8.
Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L. TGF-β-dependent
mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt
autoimmune diabetes. Nat Med. 2003;9(9):1202–8.
9.
Gandhi R, Farez MF, Wang Y, Kozoriz D, Quintana FJ, Weiner HL. Cutting edge: human
latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol.
2010;184(9):4620–4.
10.
Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified
anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest.
2005;115(10):2904–13.
11.
Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibitory receptor expression
depends more dominantly on differentiation and activation than “exhaustion” of human
CD8 T cells. Front Immunol. 2013;4(DEC):1–15.
12.
Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy JA, Harris KM, et al. Partial exhaustion
of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci
Immunol. 2016;1(5):7793–802.
13.
Horwitz DA, Pan S, Ou JN, Wang J, Chen M, Gray JD, et al. Therapeutic polyclonal human
CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo. Clin Immunol. 2013;149(PB):450–63.
14.
Wallberg M, Recino A, Phillips J, Howie D, Vienne M, Paluch C, et al. Anti-CD3 treatment
up-regulates programmed cell death protein-1 expression on activated effector T cells
and severely impairs their inflammatory capacity. Immunology. 2017;151(2):248–60.
15.
Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human
CD8+ T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010;40(10):2891–901.
16.
Hamalainen H, Zhou H, Chou W, Hashizume H, Heller R, Lahesmaa R. Distinct gene expression
profiles of human type 1 and type 2 T helper cells. Genome Biol. 2001;2(7):RESEARCH0022.
17.
Hess K, Yang Y, Golech S, Sharov A, Becker KG, Weng NP. Kinetic assessment of general
gene expression changes during human naive CD4+ T cell activation. Int Immunol. 2004;16(12):1711–21.
18.
Birzele F, Fauti T, Stahl H, Lenter MC, Simon E, Knebel D, et al. Next-generation
insights into regulatory T cells: Expression profiling and FoxP3 occupancy in Human.
Nucleic Acids Res. 2011;39(18):7946–60.
19.
Zhao S, Fung-Leung WP, Bittner A, Ngo K, Liu X. Comparison of RNA-Seq and microarray
in transcriptome profiling of activated T cells. PLoS One. 2014;9(1).
20.
Weber C, Weber KSC, Klier C, Gu S, Wank R, Horuk R, et al. Specialized roles of the
chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T H 1-like /
CD45RO + T cells Specialized roles of the chemokine receptors CCR1 and CCR5 in the
recruitment of monocytes and T H 1-like / CD45RO ϩ T cells. Blood. 2011;97(4):1144–6.
21.
Biedermann T, Rocken M, Carballido JM. TH1 and TH2 lymphocyte development and regulation
of TH cell-mediated immune responses of the skin. J Investig Dermatol Symp Proc. 2004;9(1):5–14.
22.
Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, et al. Interleukin
21 Is a T Helper (Th) Cell 2 Cytokine that Specifically Inhibits the Differentiation
of Naive Th Cells into Interferon γ–producing Th1 Cells. J Exp Med. 2002;196(7):969–77.
23.
Maddur MS, Miossec P, Kaveri S V., Bayry J. Th17 cells: Biology, pathogenesis of autoimmune
and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181(1):8–18.
24.
Schraml BU, Hildner K, Ise W, Lee W, Whitney A, Solomon B, et al. The AP-1 transcription
factor Batf controls TH 17 differentiation. Nature. 2009;460(7253):405–9.
25.
Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T Cells: Mechanisms of Differentiation
and Function. Annu Rev Immunol. 2012;30(1):531–64.
26.
Xin Chen and Joost J. Oppenhein. Resolving the identity myth: key markers of functional
CD4+FOXP3+ regulatory T cells. Int Immunopharmacol. 2011;11(10):1489–96.
27.
Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who’s who of T-cell differentiation:
Human memory T-cell subsets. Eur J Immunol. 2013;43(11):2797–809.
28.
Liu J, Chen D, Nie GD, Dai Z. CD8+CD122+ T-Cells: A Newly Emerging Regulator with
Central Memory Cell Phenotypes. Front Immunol. 2015;6(October):6–11.
29.
Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg M, et al. Human
and Mouse CD8+CD25+FOXP3+ Regulatory T Cells at Steady State and during Interleukin-2
Therapy. Front Immunol. 2015;6(April):2–11.
30.
Park B V., Pan F. The role of nuclear receptors in regulation of Th17/Treg biology
and its implications for diseases. Cell Mol Immunol. 2015;12(5):533–42.
31.
Silva HM, Vieira PMMM, Costa PLN, Pimentel BMS, Moro AM, Kalil J, et al. Novel humanized
anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral
blood mononuclear cells. Immunol Lett. 2009;125(2):129–36.
32.
Shu L, Qi CF, Schlom J, Kashmiri S V. Secretion of a single-gene-encoded immunoglobulin
from myeloma cells. Proc Natl Acad Sci U S A. 1993;90(17):7995–9.
33.
Vaz De Andrade E, Freitas SM, Ventura MM, Maranhão AQ, Brigido MM. Thermodynamic basis
for antibody binding to Z-DNA: Comparison of a monoclonal antibody and its recombinant
derivatives. Biochim Biophys Acta - Gen Subj. 2005;1726(3):293–301.
34.
Secchiero P, Sblattero DI, Chiaruttinf C, Melloni E, Macor P, Zorzet S, et al. Selection
and characterization of a novel agonistic human recombinant anti-trail-r2 minibody
with anti-leukemic activity Department ofMorphology and Embryology , University ofFerrara
, Ferrara ; 1 Department of Medical Sciences , University Piemonte Orien. 2009;22(I):73–83.
35.
Han T, Abdel-Motal UM, Chang D, Sui J, Muvaffak A, Campbell J, et al. Human Anti-CCR4
Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma. PLoS One. 2012;7(9):e44455.
36.
Abdel-Motal UM, Harbison C, Han T, Pudney J, Anderson DJ, Zhu Q, et al. Prolonged
expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital
tract by AAV gene transfer. Gene Ther. 2014;21(9):802–10.
37.
Van Wauwe JP, Goossens JG. The mitogenic activity of OKT3 and anti-Leu 4 monoclonal
antibodies: A comparative study. Cell Immunol. 1983;77(1):23–9.
38.
Chatenoud LFCLC et al. In vivo cell activation following OKT3 administration.pdf.
Transplantation. 1990;49(4):697–702.
39.
Malcolm SL, Smith EL, Bourne T, Shaw S. A humanised mouse model of cytokine release :
Comparison of CD3-speci fi c antibody fragments. J Immunol Methods. 2012;384(1–2):33–42.
40.
Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation
of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3??1(Ala-Ala). J Clin Invest.
2003;111(3):409–18.
41.
Li Li, Nishio Junko MA van et al. Differential response of regulatory and conventional
CD4+ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action?
J Immunol. 2013;197(7):3694–704.
42.
Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside.
Nat Rev Immunol. 2003;3(2):123–32.
43.
Besançon A, Baas M, Goncalves T, Valette F, Waldmann H, Chatenoud L, et al. The induction
and maintenance of transplant tolerance engages both regulatory and anergic CD4+ T
cells. Front Immunol. 2017;8(MAR):1–11.
44.
Bluestone J, Mackay C, O’Shea J, Stockinger B. The functional plasticity of T cell
subsets. Nat Rev Immunol. 2009;9(11):811–6.
45.
Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, et al. Amelioration of acute graft-versus-host
disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead
box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17
balance in a mouse model. Transfusion. 2012;52(6):1333–47.
46.
Sousa IG, do Almo MM, Simi KCR, Bezerra MAG, Andrade RV, Maranhão AQ, et al. MicroRNA
expression profiles in human CD3+ T cells following stimulation with anti-human CD3
antibodies. BMC Res Notes. 2017;10(1):124.
47.
Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, et al. The transcription
factors Blimp-1 and IRF4 jointly control the differentiation and function of effector
regulatory T cells. Nat Publ Gr. 2011;12(4):304–11.
48.
Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely
correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med.
2006;203(7):1701–11.
49.
Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, et al. CD4+CD25+CD127low/- regulatory
T cells express Foxp3 and suppress effector T cell proliferation and contribute to
gastric cancers progression. Clin Immunol. 2009;131(1):109–18.
50.
Saraiva M, Garra AO. The regulation of IL 10 production by immune cells. Nat Rev
Immunol. 2010;10(3):170–81.
51.
Dummer CD, Carpio VN, Felipe L, Gonçalves S, Manfro RC, Veronese FV. FOXP3 + regulatory
T cells : From suppression of rejection to induction of renal allograft tolerance
☆. Transpl Immunol. 2012;26(1):1–10.
52.
Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, et al. Remodeling T cell compartments
during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol. 2017;319:3–9.
53.
Speiser DE, Utzschneider DT, Oberle SG, Münz C, Romero P, Zehn D. T cell differentiation
in chronic infection and cancer: Functional adaptation or exhaustion?. Vol. 14, Nature
Reviews Immunology. Nature Publishing Group; 2014. p. 768–74.
54.
Curran TA, Jalili RB, Farrokhi A, Ghahary A. IDO expressing fibroblasts promote the
expansion of antigen specific regulatory T cells. Immunobiology. 2014;219(1):17–24.
55.
Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modulation
of tryptophan catabolism by human leukemic cells results in the conversion of. Blood.
2006;109:2871–8.
56.
Ratajczak P, Janin A, Peffault de Larour R, Koch L, Roche B, Munn D, et al. IDO in
Human Gut Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2012;18(1):150–5.
57.
Babraham Institute. Barbraham Bioinformatics, Cambridge.
58.
University of California Santa Cruz. USCS Genome Browser.
59.
Hoffmann S, Otto C, Kurtz S, Sharma CM, Khaitovich P, Vogel J, et al. Fast mapping
of short sequences with mismatches, insertions and deletions using index structures.
PLoS Comput Biol. 2009;5(9):1–10.
60.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map
format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
61.
Anders S, Pyl PT, Huber W. HTSeq-A Python framework to work with high-throughput sequencing
data. Bioinformatics. 2015;31(2):166–9.
62.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. Genome Biol. 2014;15(12):1–21.
63.
Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: Modeling the evolution of gene function,
and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res.
2013;41(D1):377–86.
64.
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr : interactive
and collaborative HTML5 gene list enrichment analysis tool. 2013;